What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?

We have data that chemotherapy is generally superior to next-line ARSI. However, we are still lacking definitive data on sequencing chemotherapy and PARPi. Based on my clinical experience and what can try to learn from studies regarding the toxicities of chemotherapy and PARPi, I believe that PARPi ...

Based on the available data, to most accurately answer this difficult question of “What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC, after progression on first line combinations?” I would first separate it into two groups, BRCA+/mCRPC and HRR+/mCRPC, and choose my...